RE: Phase IIIIt's not just if the company wants to do phase 3 and there is not side effects than it is a go...the FDA has to review it to see if it is worth spending their resources on. If you look at the info on what kind of manpower in days it takes the FDA to approve a drug it is staggering. The FDA needs to believe it is worth their effort too... they do not have unlimited resources.
Straight from the NR
"...management of the Company believes that it would be worthwhile to proceed to an end-of-Phase II meeting with the FDA in which they will seek approval to proceed with a Phase III stroke study for NTx®-265. Management's objective is to have such meeting in October of this year. There can be no assurance that the FDA will grant approval for a Phase III stroke trial."